eral new appointments to the panel in January 2012, consistent with scheduled rotations; others had been members for 2 or more years before the panel was reconvened for the update. We agree with the importance of minimizing conflict of interest and bias within guidelines panels; therefore, the panel does not rely simply on disclosure of conflict of interest.Accordingly, the panel manages conflict of interest with (1) exclusion of individuals who would have a clear financial conflict; (2) prior disclosure and discussion within the committee of circumstances that could be perceived as a potential conflict; (3) recusal from discussion and writing in areas in which potential or perceived conflict may exist; and (4) abstention by panel members from pharmaceutical company-sponsored promotional or marketing activities for a minimum of 1 year prior to joining the panel and throughout the duration of participation. Discussion of these policies and roles of specific panel members was abbreviated in our article because of space limitations.In the complex and fast-paced field of antiretroviral therapy, the IAS-USA Panel believes that there is a need for data to be evaluated by experts who specialize in the field, including those who design and conduct clinical trials. At the same time, the panel is mindful of the need to avoid, disclose, and manage potential and perceived conflicts, whether financial or institutional, involving industry-or governmentsponsored research. Including the panels mentioned above, we believe no human immunodeficiency virus antiretroviral guidelines panel has a stronger or more transparent conflict of interest policy than the IAS-USA Panel.